Prognostic value of the proliferation marker Ki-67 in laryngeal carcinoma: Results of the Accelerated Radiotherapy with Carbogen Breathing and Nicotinamide phase III randomized trial

Saskia E. Rademakers; Ilse J. Hoogsteen; Paul F. Rijken; Chris H. Terhaard; Patricia A. Doornaert; Johannes A. Langendijk; Piet Van Den Ende; Albert J. Van Der Kogel; Johan Bussink; Johannes H. Kaanders

doi:10.1002/hed.23569

Prognostic value of the proliferation marker Ki-67 in laryngeal carcinoma: Results of the Accelerated Radiotherapy with Carbogen Breathing and Nicotinamide phase III randomized trial

Saskia E. Rademakers^*, Ilse J. Hoogsteen, Paul F. Rijken, Chris H. Terhaard, Patricia A. Doornaert, Johannes A. Langendijk, Piet Van Den Ende, Albert J. Van Der Kogel, Johan Bussink, Johannes H. Kaanders

^*Corresponding author for this work

Cancer

Research output: Contribution to journal › Article › Academic › peer-review

3 Citations (Scopus)

Abstract

Background

The prognostic and predictive value of the proliferation marker Ki-67 was investigated in a randomized trial comparing accelerated radiotherapy with carbogen breathing and nicotinamide (ARCON) to accelerated radiotherapy in laryngeal carcinoma.

Methods

Labeling index of Ki-67 (Li Ki-67) in immunohistochemically stained biopsies and the colocalization with carbonic anhydrase IX (CAIX) were related to tumor control and patient survival.

Results

On average, node-positive patients had a higher Li Ki-67 (median 14% vs 8%; p < .01). In patients with a high Li Ki-67, the 5-year regional control and metastases-free survival were 79% versus 96% (p < .01) and 71% versus 88% (p = .05) for accelerated radiotherapy and ARCON, respectively. The 5-year local control and disease-specific survival were not significantly different. Patients with low Ki-67 expression had an excellent outcome with accelerated radiotherapy alone.

Conclusion

Patients with laryngeal carcinomas with high proliferative activity are at increased risk of regional and distant metastases formation. This risk can be reduced by treatment with ARCON.

Original language	English
Pages (from-to)	171-176
Number of pages	6
Journal	Head and Neck
Volume	37
Issue number	2
DOIs	https://doi.org/10.1002/hed.23569
Publication status	Published - 1 Feb 2015

Keywords

Hypoxia
Laryngeal carcinoma
Prognostic
Proliferation
Radiotherapy

Access to Document

10.1002/hed.23569

Cite this

Rademakers, S. E., Hoogsteen, I. J., Rijken, P. F., Terhaard, C. H., Doornaert, P. A., Langendijk, J. A., Van Den Ende, P., Van Der Kogel, A. J., Bussink, J., & Kaanders, J. H. (2015). Prognostic value of the proliferation marker Ki-67 in laryngeal carcinoma: Results of the Accelerated Radiotherapy with Carbogen Breathing and Nicotinamide phase III randomized trial. Head and Neck, 37(2), 171-176. https://doi.org/10.1002/hed.23569

@article{2106cae05d704f7685e580fbf68a3ffa,

title = "Prognostic value of the proliferation marker Ki-67 in laryngeal carcinoma: Results of the Accelerated Radiotherapy with Carbogen Breathing and Nicotinamide phase III randomized trial",

abstract = "BackgroundThe prognostic and predictive value of the proliferation marker Ki-67 was investigated in a randomized trial comparing accelerated radiotherapy with carbogen breathing and nicotinamide (ARCON) to accelerated radiotherapy in laryngeal carcinoma.MethodsLabeling index of Ki-67 (Li Ki-67) in immunohistochemically stained biopsies and the colocalization with carbonic anhydrase IX (CAIX) were related to tumor control and patient survival.ResultsOn average, node-positive patients had a higher Li Ki-67 (median 14% vs 8%; p < .01). In patients with a high Li Ki-67, the 5-year regional control and metastases-free survival were 79% versus 96% (p < .01) and 71% versus 88% (p = .05) for accelerated radiotherapy and ARCON, respectively. The 5-year local control and disease-specific survival were not significantly different. Patients with low Ki-67 expression had an excellent outcome with accelerated radiotherapy alone.ConclusionPatients with laryngeal carcinomas with high proliferative activity are at increased risk of regional and distant metastases formation. This risk can be reduced by treatment with ARCON.",

keywords = "Hypoxia, Laryngeal carcinoma, Prognostic, Proliferation, Radiotherapy",

author = "Rademakers, {Saskia E.} and Hoogsteen, {Ilse J.} and Rijken, {Paul F.} and Terhaard, {Chris H.} and Doornaert, {Patricia A.} and Langendijk, {Johannes A.} and {Van Den Ende}, Piet and {Van Der Kogel}, {Albert J.} and Johan Bussink and Kaanders, {Johannes H.}",

year = "2015",

month = feb,

day = "1",

doi = "10.1002/hed.23569",

language = "English",

volume = "37",

pages = "171--176",

journal = "Head and Neck",

issn = "1043-3074",

publisher = "John Wiley & Sons Inc.",

number = "2",

}

Rademakers, SE, Hoogsteen, IJ, Rijken, PF, Terhaard, CH, Doornaert, PA, Langendijk, JA, Van Den Ende, P, Van Der Kogel, AJ, Bussink, J & Kaanders, JH 2015, 'Prognostic value of the proliferation marker Ki-67 in laryngeal carcinoma: Results of the Accelerated Radiotherapy with Carbogen Breathing and Nicotinamide phase III randomized trial', Head and Neck, vol. 37, no. 2, pp. 171-176. https://doi.org/10.1002/hed.23569

Prognostic value of the proliferation marker Ki-67 in laryngeal carcinoma: Results of the Accelerated Radiotherapy with Carbogen Breathing and Nicotinamide phase III randomized trial. / Rademakers, Saskia E.; Hoogsteen, Ilse J.; Rijken, Paul F. et al.
In: Head and Neck, Vol. 37, No. 2, 01.02.2015, p. 171-176.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Prognostic value of the proliferation marker Ki-67 in laryngeal carcinoma

T2 - Results of the Accelerated Radiotherapy with Carbogen Breathing and Nicotinamide phase III randomized trial

AU - Rademakers, Saskia E.

AU - Hoogsteen, Ilse J.

AU - Rijken, Paul F.

AU - Terhaard, Chris H.

AU - Doornaert, Patricia A.

AU - Langendijk, Johannes A.

AU - Van Den Ende, Piet

AU - Van Der Kogel, Albert J.

AU - Bussink, Johan

AU - Kaanders, Johannes H.

PY - 2015/2/1

Y1 - 2015/2/1

N2 - BackgroundThe prognostic and predictive value of the proliferation marker Ki-67 was investigated in a randomized trial comparing accelerated radiotherapy with carbogen breathing and nicotinamide (ARCON) to accelerated radiotherapy in laryngeal carcinoma.MethodsLabeling index of Ki-67 (Li Ki-67) in immunohistochemically stained biopsies and the colocalization with carbonic anhydrase IX (CAIX) were related to tumor control and patient survival.ResultsOn average, node-positive patients had a higher Li Ki-67 (median 14% vs 8%; p < .01). In patients with a high Li Ki-67, the 5-year regional control and metastases-free survival were 79% versus 96% (p < .01) and 71% versus 88% (p = .05) for accelerated radiotherapy and ARCON, respectively. The 5-year local control and disease-specific survival were not significantly different. Patients with low Ki-67 expression had an excellent outcome with accelerated radiotherapy alone.ConclusionPatients with laryngeal carcinomas with high proliferative activity are at increased risk of regional and distant metastases formation. This risk can be reduced by treatment with ARCON.

AB - BackgroundThe prognostic and predictive value of the proliferation marker Ki-67 was investigated in a randomized trial comparing accelerated radiotherapy with carbogen breathing and nicotinamide (ARCON) to accelerated radiotherapy in laryngeal carcinoma.MethodsLabeling index of Ki-67 (Li Ki-67) in immunohistochemically stained biopsies and the colocalization with carbonic anhydrase IX (CAIX) were related to tumor control and patient survival.ResultsOn average, node-positive patients had a higher Li Ki-67 (median 14% vs 8%; p < .01). In patients with a high Li Ki-67, the 5-year regional control and metastases-free survival were 79% versus 96% (p < .01) and 71% versus 88% (p = .05) for accelerated radiotherapy and ARCON, respectively. The 5-year local control and disease-specific survival were not significantly different. Patients with low Ki-67 expression had an excellent outcome with accelerated radiotherapy alone.ConclusionPatients with laryngeal carcinomas with high proliferative activity are at increased risk of regional and distant metastases formation. This risk can be reduced by treatment with ARCON.

KW - Hypoxia

KW - Laryngeal carcinoma

KW - Prognostic

KW - Proliferation

KW - Radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=84921436651&partnerID=8YFLogxK

U2 - 10.1002/hed.23569

DO - 10.1002/hed.23569

M3 - Article

C2 - 24347430

AN - SCOPUS:84921436651

SN - 1043-3074

VL - 37

SP - 171

EP - 176

JO - Head and Neck

JF - Head and Neck

IS - 2

ER -

Prognostic value of the proliferation marker Ki-67 in laryngeal carcinoma: Results of the Accelerated Radiotherapy with Carbogen Breathing and Nicotinamide phase III randomized trial

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this